Market News / Story
argenx SE (ARGX) Halts Phase 3 UNITY Trial for Futility
·
argenx SE will discontinue the Phase 3 UNITY study of efgartigimod SC in Sjögren's disease after an IDMC recommended stopping for futility at interim; safety was consistent with prior profile. Material Details #DetailAI Analyst View1Stops Phase 3 UNITY for futilityRemoves a potential label expansion and revenue stream; likely negative for near-term sentiment.2IDMC interim analysis callIndependent assessment reduces debate on efficacy signal; lowers odds of…